%0 Journal Article %A Gehani, A. A. %A Hammoudeh, M. %T Selected Abstracts From Other Journals %D 2009 %J Qatar Medical Journal, %V 2009 %N 1 %@ 2227-0426 %C 26 %R https://doi.org/10.5339/qmj.2009.1.26 %I Hamad bin Khalifa University Press (HBKU Press), %X Background: Since some patients with psoriatic arthritis do not respond to typical drug treatments, alternatives are needed. Findings suggest that interleukins 12 and 23 might affect clinical symptoms and pathological joint changes of psoriatic arthritis. Ustekinumab is a human monoclonal antibody that inhibits receptor-binding of these cytokines. We aimed to assess the efficacy and safety of ustekinumab for psoriatic arthritis in this phase II study. %U https://www.qscience.com/content/journals/10.5339/qmj.2009.1.26